Protective effects of combined therapy of gliclazide with curcumin in experimental diabetic neuropathy in rats

Behav Pharmacol. 2012 Apr;23(2):153-61. doi: 10.1097/FBP.0b013e3283512c00.

Abstract

Diabetic neuropathy is the most common chronic complication of diabetes. The aim of the present study was to evaluate the protective effects of curcumin against neuropathy in gliclazide-treated diabetic rats. Diabetes was induced by an intraperitoneal injection of streptozotocin (45 mg/kg). Diabetic animals were given gliclazide (10 mg/kg, orally) alone or combined with curcumin (100 mg/kg, orally) or gabapentin (30 mg/kg, intraperitoneally as a positive control). Behavioral responses to thermal (hot plate and tail flick) and mechanical (tail pinch) pain, and some biochemical tests (serum glucose, C-peptide, peroxynitrite, lipid peroxides, and tumor necrosis factor-α) were assessed after 5 consecutive weeks of daily treatment. Combined treatment of curcumin with gliclazide significantly increased hot-plate and tail-flick latencies in comparison with that of the diabetic control group. The threshold of mechanical hyperalgesia was also significantly elevated. Serum glucose and C-peptide levels were significantly increased in the combined treatment compared with the diabetic control group, whereas serum levels of peroxynitrite, lipid peroxide, and tumor necrosis factor-α production were significantly decreased. The data suggest that the combination of curcumin with gliclazide may protect against the development of diabetic neuropathy, with favorable effects with respect to the gliclazide/gabapentin combination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amines / administration & dosage
  • Amines / pharmacology
  • Amines / therapeutic use*
  • Analgesics / administration & dosage
  • Analgesics / pharmacology
  • Analgesics / therapeutic use
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Blood Glucose / drug effects
  • C-Peptide / blood
  • Curcumin / administration & dosage
  • Curcumin / pharmacology
  • Curcumin / therapeutic use*
  • Cyclohexanecarboxylic Acids / administration & dosage
  • Cyclohexanecarboxylic Acids / pharmacology
  • Cyclohexanecarboxylic Acids / therapeutic use*
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy*
  • Diabetic Neuropathies / blood
  • Diabetic Neuropathies / prevention & control*
  • Drug Therapy, Combination / methods
  • Gabapentin
  • Gliclazide / administration & dosage
  • Gliclazide / pharmacology
  • Gliclazide / therapeutic use*
  • Hyperalgesia / drug therapy
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Lipid Peroxides / blood
  • Male
  • Pain Threshold / drug effects
  • Peroxynitrous Acid / blood
  • Rats
  • Rats, Sprague-Dawley
  • Tumor Necrosis Factor-alpha / blood
  • gamma-Aminobutyric Acid / administration & dosage
  • gamma-Aminobutyric Acid / pharmacology
  • gamma-Aminobutyric Acid / therapeutic use*

Substances

  • Amines
  • Analgesics
  • Anti-Inflammatory Agents, Non-Steroidal
  • Blood Glucose
  • C-Peptide
  • Cyclohexanecarboxylic Acids
  • Hypoglycemic Agents
  • Lipid Peroxides
  • Tumor Necrosis Factor-alpha
  • Peroxynitrous Acid
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Gliclazide
  • Curcumin